Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: Findings and future implications

Frontiers in Pharmacology

Volumn 5 JUN, Issue , 2014, Pages

  Godman, Brian ^a,b,c   Wettermark, Bjorn ^a,d   van Woerkom, Menno ^e   Fraeyman, Jessica ^f   Alvarez Madrazo, Samantha ^b   Berg, Christian ^g   Bishop, Iain ^h   Bucsics, Anna ^i,j   Campbell, Stephen ^k   Finlayson, Alexander E ^l   Fürst, Jurij ^m   Garuoliene, Kristina ^n,o   Herholz, Harald ^p   Kalaba, Marija ^j   Laius, Ott ^q   Piessnegger, Jutta ^j   Sermet, Catherine ^r   Schwabe, Ulrich ^s   Vlahovic Palcevski, Vera V ^t   Markovic Pekovic, Vanda ^u,v   Voncina, Luka ^w   Malinowska, Kamila ^x,y   Zara, Corinne ^z   Gustafsson, Lars L ^a   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d STOCKHOLM COUNTY COUNCIL   (Sweden)

^e Dutch Institute for Proper Use of Medicines   (Netherlands)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^h INFORMATION SERVICES DIVISION   (United Kingdom)

ⁱ UNIVERSITY OF VIENNA   (Austria)

^j Department of Finance Faculty of Business Economics and Statistics University of Vienna ^*  (Serbia)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m Health Insurance Institute   (Slovenia)

ⁿ VILNIUS UNIVERSITY   (Lithuania)

^o National Health Insurance Fund   (Lithuania)

^p Kasemarzliche Vereinigung Hessen   (Germany)

^q State Agency of Medicines   (Estonia)

^r IRDES   (France)

^s UNIVERSITY OF HEIDELBERG   (Germany)

^t KBC RIJEKA   (Croatia)

^u UNIVERSITY OF BANJA LUKA   (Bosnia and Herzegovina)

^v MINISTRY OF HEALTH AND SOCIAL WELFARE   (Bosnia and Herzegovina)

^w Ministry of Health   (Croatia)

^x School of Public Health   (Poland)

^y National Health Fund   (Poland)

^z C Agy Hlth Technol Assess Res   (Spain)

more..

Author keywords

Demand side measures; Drug utilization studies; Generics; PPIs; Renin angiotensin inhibitor drugs; Statins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PROTON PUMP INHIBITOR; ROSUVASTATIN;

AMBULATORY CARE; AUSTRIA; BELGIUM; BOSNIA AND HERZEGOVINA; CROATIA; DENMARK; DRUG COST; DRUG USE; DRUG UTILIZATION; GERMANY; HEALTH CARE POLICY; IRELAND; NETHERLANDS; NORWAY; OBSERVATIONAL STUDY; PORTUGAL; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; REVIEW; SPAIN; SWEDEN; UNITED KINGDOM; WESTERN EUROPE;

EID: 84904756503     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00106     Document Type: Review

References (42)

1. Baumgärtel, C., Godman, B., Malmström, R., Andersen, M., Abuelkhair, M., and Abdu, S. (2012). What lessons can be learned from the launch of generic clopidogrel? GABI 1, 58-68. doi: 10.5639/gabij.2012.0102.016
2. Bennie, M., Bishop, I., Godman, B., Campbell, S., Miranda, J., Finlayson, A. E., et al. (2013). Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? Qual. Prim. Care 21, 7-15.
3. Bennie, M., Godman, B., Bishop, I., and Campbell, S. (2012). Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12, 125-130. doi: 10.1586/erp.11.98
4. Civaner, M. (2012). Sale strategies of pharmaceutical companies in a "pharmerging" country: the problems will not improve if the gaps remain Health Policy 106, 25-32. doi: 10.1016/j.healthpol.2012.05.006
5. Dylst, P., Vulto, A., Godman, B., and Simoens, S. (2013). Generic medicines: solutions for a sustainable drug market? Appl. Health Econ. Health Policy 11, 437-443. doi: 10.1007/s40258-013-0043-z
6. Dylst, P., Vulto, A., Simoens, S. (2011). Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy 101, 146-152. doi: 10.1016/j.healthpol.2011.03.004
7. Experts in chronic myeloid leukemia. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121, 4439-4442. doi: 10.1182/blood-2013-03-490003
8. Ferrario, A., and Kanavos, P. (2013). Managed Entry Agreements for Pharmaceuticals: The European Experience. Available online at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf
9. Fraeyman, J., Van Hal, G., De Loof, H., Remmen, R., De Meyer, G. R., and Beutels, P. (2012). Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium. Acta Clin. Belg. 67, 160-171.
10. Fraeyman, J., Van Hal, G., Godman, B., and Beutels, P. (2013). The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Rev. Pharmacoecon. Outcomes Res. 13, 141-151. doi: 10.1586/erp.12.88
11. Garattini, S., Bertele, V., Godman, B., Haycox, A., Wettermark, B., Gustafsson, L. L., et al. (2008). Enhancing the rational use of new medicines across European healthcare systems-a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138. doi: 10.1007/s00228-008-0537-z
12. Godman, B., Abuelkhair, M., Vitry, A., Abdu, S., Bennie, M., Bishop, I., et al. (2012a). Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI 1, 69-83. doi: 10.5639/gabij.2012.0102.017
13. Godman, B., Bennie, M., Baumgärtel, C., Sovi c-Brkieic, L., Burkhardt, T., Fürst, J., et al. (2012b). Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia 13(Suppl. 3), 5-20.
14. Godman, B., Bennie, M., Bucsics, A., Hesse, U., Martin, A., Miranda, J., et al. (2013c). Variable approaches in Europe to the availability of generic losartan; implications for the future. Clin. Ther. 35, e36-e37. doi: 10.1016/j.clinthera.2013.07.088
15. Godman, B., Campbell, S., Suh, H. S., Finlayson, A. E., Bennie, M., Gustafsson, L. L. (2013a). Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J. Health Tech. Assess. 1, 27-42.
16. Godman, B., De Bruyn, K., Miranda, J., Raschi, E., Bennie, M., Barbui, C., et al. (2013f). Generic atypical antipsychotic drugs in Belgium; their influence and implications. J. Comp. Eff. Res. 2, 551-561. doi: 10.2217/cer.13.75
17. Godman, B., Persson, M., Miranda, J., Barbui, C., Bennie, M., Bennett, K., et al. (2013e). Can authorities take full advantage of the availability of generic atypical antipsychotic drugs? Implications for the future. Clin. Ther. 35, e99-e100. doi: 10.1016/j.clinthera.2013.07.291
18. Godman, B., Persson, M., Miranda, J., Barbui, C., Bennie, M., Finlayson, A. E. et al. (2013d). Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. J. Pharm. Health Serv. Res. 4, 139-150. doi: 10.1111/jphs.12025
19. Godman, B., Sakshaug, S., Berg, C., Wettermark, B., and Haycox, A. (2011b). Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11, 121-129. doi: 10.1586/erp.10.87
20. Godman, B., Schwabe, U., Selke, G., and Wettermark, B. (2009). Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics 27, 435-438. doi: 10.2165/00019053-200927050-00010
21. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2011a). Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1:141. doi: 10.3389/fphar.2010.00141
22. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., Burkhardt, T., et al. (2010b). Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707-722. doi: 10.1586/erp.10.72
23. Godman, B., Shrank, W., Wettermark, B., Andersen, M., Bishop, I., Burkhardt, T., et al. (2010a). Use of generics-a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470-2494. doi 10.3390/ph/3082470
24. Godman, B., Wettermark, B., Miranda, J., Bennie, M., Martin, A., and Malmström, R. E. (2013b). Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. Int. J. Clin. Pract. 67, 853-862. doi: 10.1111/ijcp.12130
25. Hesse, U., Godman, B., Petzold, M., Martin, A., and Malmström, R. E. (2013). Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark; implications for other countries. Appl. Health Econ. Health Pol. 11, 677-685. doi: 10.1007/s40258-013-0059-4
26. Klemp, M., Frønsdal, K., Facey, K., and HTAi Policy Forum. (2011). What principles should govern the use of managed entry agreements? Int. J. Technol. Assess. Health Care 27, 77-83. doi: 10.1017/S0266462310001297
27. Kwon, H. Y., Hong, J. M., Godman, B., and Yang, B. M. (2013). Price cuts and drug spending in south korea: the case of antihyperlipidemic agents. Health Policy 112, 217-226. doi: 10.1016/j.healthpol.2013.08.011
28. Malmström, R. E., Godman, B., Diogene, E., Baumgärtel, C., Bennie, M., Bishop, I., et al. (2013). Dabigatran - a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs. Front. Pharmacol. 4, 1-19. doi: 10.3389/fphar.2013.00039
29. Markovic-Pekovic, V., Ranko Škrbic, R., Godman, B., and Gustafsson, L. L. (2012). Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev. Pharmacoecon. Outcomes Res. 5, 661-671. doi: 10.1586/erp.12.48
30. Martin, A., Godman, B., Miranda, J., Tilstone, J., Saleem, N., Olsson, E., et al. (2014). Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. J. Comp. Eff. Res. 3, 41-51. doi: 10.2217/cer.13.83
31. Moon, J., Flett, A., Godman, B., Grosso, A. M., and Wierzbicki, A. S. (2010). Getting better value from the NHS drug budget. BMJ 341:c6449. doi: 10.1136/bmj.c6449
32. NICE. (2014). Thousands More Could be Offered Statins. Available online at: http://www.nice.org.uk/newsroom/news/ThousandsMoreCouldBeOfferedStatins.jsp (Accessed March 2014).
33. Norman, C., Zarrinkoub, R., Hasselström, J., Godman, B., Granath, F., and Wettermark, B. (2008). Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63, 1320-1326. doi: 10.1111/j.1742-1241.2009.02129.x
34. Olsson, E., Ingman, P., Ahmed, A., and Sporrong, S. (2014). Pharmacist-patient communication in Swedish community pharmacists. Res. Social Adm. Pharm. 10, 149-155. doi: 10.1016/j.sapharm.2013.03.001
35. Pettersson, B., Hoffmann, M., Per Wändell, P., and Levin, L. Å. (2012). Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 104, 84-91. doi: 10.1016/j.healthpol.2011.10.010
36. Usher-Smith, J., Ramsbottom, T., Pearmain, H., and Kirby, M. (2008). Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480-484. doi: 10.1111/j.1742-1241.2007.01690.x
37. van Woerkom, M., Piepenbrink, J. F., Godman, B., Metz, J. D., Campbell, S., Bennie, M., et al. (2012). Ongoing measures to enhance the efficiency of prescribing of PPIs and statins in the Netherlands; influence and future implications. J. Comp. Eff. Res. 1, 527-538. doi: 10.2217/cer.12.52
38. Voncina, L., Strizrep, T., Godman, B., Bennie, M., Bishop, I., Campbell, S., et al. (2011). Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11, 469-479. doi: 10.1586/erp.11.42
39. Weng, T. C., Yang, Y. H., Lin, S. J., and Tai, S. H. (2010). A systematic review and meta-analysis on the therapeutic equivalence of statins. J. Clin. Pharm. Ther. 35, 139-151. doi: 10.1111/j.1365-2710.2009.01085.x
40. Wettermark, B., Godman, B., Jacobsson, B., and Haaijer-Ruskamp, F. (2009). Soft regulations in pharmaceutical policymaking-an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 1-11. doi: 10.1007/BF03256147
41. Wettermark, B., Godman, B., Neovius, M., Hedberg, N., Mellgren, T. O., and Kahan, T. (2010). Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94, 221-229. doi: 10.1016/j.healthpol.2009.09.014
42. World Health Organization (WHO). (2003). Introduction to Drug Utilisation Research. Available online at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf